Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5346
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBolaman, Z.-
dc.contributor.authorKöseoglu, M.-
dc.contributor.authorAyyildiz, O.-
dc.contributor.authorKadiköylü, G.-
dc.contributor.authorSönmez, H.M.-
dc.contributor.authorDemir, S.-
dc.contributor.authorMüftuüoglu, E.-
dc.date.accessioned2019-08-16T11:45:13Z-
dc.date.available2019-08-16T11:45:13Z-
dc.date.issued2002-
dc.identifier.issn0017-6559-
dc.identifier.urihttps://hdl.handle.net/11499/5346-
dc.identifier.urihttps://doi.org/10.1163/156855902760262763-
dc.description.abstractFourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 ± 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 ± 8.6 months (median 13) for all patients, 19.4 ± 4.0 months (median 19) for those achieving a complete remission, 12.50 ± 5.7 months (median 14) for patients with partial remission and 1.8 ± 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis.en_US
dc.language.isoenen_US
dc.relation.ispartofHaematologiaen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlastic phaseen_US
dc.subjectChronic myelogenous leukemiaen_US
dc.subjectHigh dose methylprednisoloneen_US
dc.subject5 aza 2' deoxycytidineen_US
dc.subjectalpha interferonen_US
dc.subjectazacitidineen_US
dc.subjectcarboplatinen_US
dc.subjectcladribineen_US
dc.subjectcytarabineen_US
dc.subjectetoposideen_US
dc.subjectfludarabineen_US
dc.subjectgranulocyte colony stimulating factoren_US
dc.subjecthydroxyureaen_US
dc.subjectimatiniben_US
dc.subjectmeprednisoneen_US
dc.subjectmitoxantroneen_US
dc.subjectprednisoloneen_US
dc.subjectvincristineen_US
dc.subjectadulten_US
dc.subjectage distributionen_US
dc.subjectarticleen_US
dc.subjectbacteremiaen_US
dc.subjectblast cell crisisen_US
dc.subjectbone marrow hypoplasiaen_US
dc.subjectcause of deathen_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjectclinical articleen_US
dc.subjectclinical trialen_US
dc.subjectconjunctivitisen_US
dc.subjectcontrolled clinical trialen_US
dc.subjectcontrolled studyen_US
dc.subjectdiarrheaen_US
dc.subjectdose responseen_US
dc.subjectdrug megadoseen_US
dc.subjectdrug tolerabilityen_US
dc.subjectfebrile neutropeniaen_US
dc.subjectfemaleen_US
dc.subjectfeveren_US
dc.subjectflushingen_US
dc.subjecthumanen_US
dc.subjectleukemia remissionen_US
dc.subjectleukopeniaen_US
dc.subjectliver dysfunctionen_US
dc.subjectlung toxicityen_US
dc.subjectmaleen_US
dc.subjectmucosa inflammationen_US
dc.subjectnausea and vomitingen_US
dc.subjectneurotoxicityen_US
dc.subjectPhiladelphia 1 chromosomeen_US
dc.subjectpneumoniaen_US
dc.subjectprognosisen_US
dc.subjectrashen_US
dc.subjectStreptococcus infectionen_US
dc.subjectsurvival timeen_US
dc.subjectvalidation processen_US
dc.subjectAdulten_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectBlast Crisisen_US
dc.subjectCytarabineen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLeukemia, Myeloid, Chronicen_US
dc.subjectMaleen_US
dc.subjectMethylprednisoloneen_US
dc.subjectMiddle Ageden_US
dc.subjectMitoxantroneen_US
dc.subjectRemission Inductionen_US
dc.subjectSurvival Analysisen_US
dc.subjectTreatment Outcomeen_US
dc.titleTreatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisoloneen_US
dc.typeArticleen_US
dc.identifier.volume32en_US
dc.identifier.issue1en_US
dc.identifier.startpage49
dc.identifier.startpage49en_US
dc.identifier.endpage57en_US
dc.identifier.doi10.1163/156855902760262763-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopus2-s2.0-0036901814en_US
dc.identifier.wosWOS:000177405200007en_US
dc.identifier.scopusqualityQ4-
dc.ownerPamukkale_University-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

1
checked on Dec 19, 2024

Page view(s)

40
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.